Rabia Malik
Neurology · San Francisco, CANPI 1184889156
Payments from drug & device makers
Across 14 payments — averaging $4451.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB Biosciences Inc.$59K
- PTC Therapeutics, Inc.$2K
- Catalyst Pharmaceuticals, Inc.$2K
- UCB, Inc.$145
- Daiichi Sankyo Inc.$120
- Axsome Therapeutics, Inc.$23
What the payments were for
- Consulting fees$1,57585%
- Food & beverage$28815%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB Biosciences Inc. | 9 | $58,952 |
| PTC Therapeutics, Inc. | 1 | $1,575 |
| Catalyst Pharmaceuticals, Inc. | 1 | $1,500 |
| UCB, Inc. | 1 | $145 |
| Daiichi Sankyo Inc. | 1 | $120 |
| Axsome Therapeutics, Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Enhertu$120
How this compares
$62,315 in reported general payments places this provider in the 85th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Radicava OrsEdaravone | 84 | $1,206,873 |
| SolirisEculizumab | 26 | $708,571 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 48 | $476,965 |
| VyvgartEfgartigimod Alfa-Fcab | 11 | $416,668 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 45 | $260,593 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 18 | $206,095 |
| RelyvrioSod Phenylbutyrat/Taurursodiol | 11 | $137,798 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 19 | $92,596 |
| NuedextaDextromethorphan Hbr/Quinidine | 15 | $22,311 |
| Riluzole | 54 | $16,209 |
| Mycophenolate Mofetil | 98 | $16,058 |
| Pregabalin | 41 | $5,240 |
| Pyridostigmine Bromide | 54 | $4,799 |
| Azathioprine | 33 | $4,043 |
| Prednisone | 170 | $2,082 |
Paid to pharmacies, not to this prescriber.
Other neurology in San Francisco
- Bruce CreeSan Francisco$8M
- Stanley PrusinerSan Francisco$6.5M
- Adam BoxerSan Francisco$5.5M
- Jennifer ClarkeSan Francisco$5.1M
- Nancy Ann Oberheim BushSan Francisco$4.6M
- Emmanuelle WaubantSan Francisco$3M
- Jill OstremSan Francisco$2M
- William JagustSan Francisco$2M
- Gil RabinoviciSan Francisco$1.9M
- Jonathan KatzSan Francisco$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.